Abraxane Approved For Treatment of Pancreatic Cancer

The FDA recently approved Abraxane for the treatment of metastatic pancreatic cancer. This is a breakthrough for Celgene (who acquired the drug with their acquisition of Abraxis), and is the first significant change in the treatment of pancreatic cancer in the last 8 years.  Results from the latest clinical trials, revealed at this year’s ASCO meeting, highlighted the drugs ability to extend the lives of pancreatic cancer patients from 3 to 6 months.

Additional News


Here are the latest additions to the Mendeley Pancreatic Cancer Genomics collection.


About Mark Fortner

I write software for scientists doing drug discovery and cancer research. I'm interested in Design Thinking, Agile Software Development, Web Components, Java, Javascript, Groovy, Grails, MongoDB, Firebase, microservices, the Semantic Web Drug Discovery and Cancer Biology.
This entry was posted in pancreatic cancer and tagged , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s